Skip to content

Neuroplast B.V.

Ongoing bankruptcy

Trading as Bioscience en biopharma, Neuroplast R&D and QC

7 financial reports
KvK
61358827
Establishment
Geleen, Limburg
Court
Limburg
Bankruptcy number
F.03/23/202

Summary

The Rechtbank Limburg declared Neuroplast B.V. bankrupt on December 5, 2023 (insolvency number F.03/23/202). It concerns a BV with its place of establishment in Maastricht (Limburg). In the Dutch Commercial Register it has KvK number 61358827. It was founded on August 29, 2014. The company also used the trade names Bioscience en biopharma en Neuroplast R&D and QC. The court appointed mr. B.L.J. Lenferink of Paulussen Advocaten N.V. as insolvency practitioner. Supervision lies with supervisory judge mr. F.J.F. Gerard. There are 7 public reports; the latest is report 7 of October 6, 2026. In addition, there are 7 financial reports; the latest is financial report 7 of October 6, 2026. Estate assets according to financial report 7: €219,421.87. Key figures according to report 7: unsecured claims €16,684,857, creditors 0 en preferential claims €1,414,457.39. Status according to report 7: completed: causes of the bankruptcy; under investigation: actio pauliana; not applicable: legal proceedings.

Over the past twelve months, 251 bankruptcies were declared in Limburg. In the municipality of Sittard-Geleen there were 27 cases. The advisering, onderzoek en specialistische zakelijke diensten sector accounted for 6 cases in this province.

Estate debts according to report 7 of October 6, 2026: €348,077 (in report 6 of January 15, 2026: €315,520).

Preferential claims according to report 7 of October 6, 2026: €1,414,457.39 (in report 6 of January 15, 2026: €1,161,663.39).

Employees according to report 7 of October 6, 2026: 32.

The company information lists Sleperweg 36, 6222NK Maastricht as a business address for Neuroplast B.V..

Submit a claim

Creditors submit their claim in writing to the insolvency practitioner, stating insolvency number F.03/23/202 and enclosing the supporting documents.

Deadline for submission
Not published

New since report 7

4 changes

Public report 7 of October 6, 2026, compared with report 6 of January 15, 2026

Compare report 6 and report 7

Changed

  • Estate debts

    €315,520 €348,077

  • Preferential claims

    €1,161,663.39 €1,414,457.39

  • Estate account balance

    €8,706.11 €28,706.11

Unchanged / ongoing

Estate assets Fin. report 7
€219,421.87, history of Estate assets

+€20,000 since financial report 6

Unsecured claims Report 7
€16,684,857, history of Unsecured claims

unchanged

Preferential Report 7
€1,414,457.39, history of Preferential

+€252,794 since report 6

Creditors Report 7
0, history of Creditors

unchanged

Employees Report 7
32, history of Employees

unchanged

Further case information

Status

Rent and lease
Mentioned Rent and lease
Causes of the bankruptcy
Completed Causes of the bankruptcy
Uit overleg met de directie maak ik de volgende (voorlopige) oorzaak op. Neuroplast had en heeft veel geld nodig om haar initiatief naar de markt te kunnen brengen. Mede als gevolg van corona heeft fase 1 veel langer geduurd en is vertraging opgelopen. De zittende aandeelhouders van de holding w ilden niet meer alleen verder investeren. Daarom is nadere externe financiering gezocht. Er zou een aan
Staff
Ongoing Staff
Sale of assets
Mentioned Sale of assets
Collection of receivables
Completed Collection of receivables
Security rights
Mentioned Security rights
Restart (going-concern sale)
Mentioned Restart (going-concern sale)
Bookkeeping obligation
Mentioned Bookkeeping obligation
Filing of annual accounts
Mentioned Filing of annual accounts
Director liability
Mentioned Director liability
Actio pauliana
Under investigation Actio pauliana
Legal proceedings
Not applicable Legal proceedings
Lawfulness investigation
Under investigation Lawfulness investigation

Recent timeline

  1. Public report of October 6, 2026 published

  2. Public financial report of October 6, 2026 published

Key documents

  • Verslag: 06-10-2026

    10-06-2026 25 p. Rechtspraak

    View
  • Financieel verslag 06-10-2026

    10-06-2026 9 p. Rechtspraak

    View
  • Vervanging curator mr J.J.M.C. Huppertz door mr B.L.J. Lenferink

    09-04-2026 1 p. Central Insolvency Register

    View
  • Verslag: 15-01-2026

    01-15-2026 25 p. Rechtspraak

    View

Frequently asked questions about Neuroplast B.V.

Who has been appointed bankruptcy trustee of Neuroplast B.V.?

mr. B.L.J. Lenferink of Paulussen Advocaten N.V. has been appointed bankruptcy trustee by the Rechtbank Limburg. The bankruptcy trustee is the point of contact for questions about the bankruptcy.

When was Neuroplast B.V. declared bankrupt?

On December 5, 2023, Neuroplast B.V. was declared bankrupt by the Rechtbank Limburg. The insolvency number of the case is F.03/23/202.

Where do I submit my claim against Neuroplast B.V.?

Send your claim in writing to the insolvency practitioner, mr. B.L.J. Lenferink of Paulussen Advocaten N.V., with the documents that support it, such as invoices and contracts. Please state insolvency number F.03/23/202.

What does the bankruptcy of Neuroplast B.V. mean for creditors?

Through the bankruptcy the company loses control of its assets. Control passes to the insolvency practitioner, who sells the assets and distributes the proceeds among the creditors in the statutory ranking. Only at the end is it usually clear whether ordinary creditors receive anything, and how much.

How do I read the reports on the bankruptcy?

So far 7 public reports have appeared, the latest on October 6, 2026. They are under Reports in this case.

Company details

Legal form
BV
SBI code
72100
Founded
August 29, 2014
KvK registration
Active
Special legal status
Bankruptcy
Trade names
Bioscience en biopharma, Neuroplast R&D and QC

Sources

Addresses

  • Trading address
    Sleperweg 36 6222 NK Maastricht
    • Built in 1990
    • kantoorfunctie
    • 934 m²
  • Correspondence address Business address Trading address
    Urmonderbaan 22 6167 RD Geleen
    municipality of Sittard-Geleen Limburg
    • Built in 2009
    • kantoorfunctie
    • 94 m²

Affiliated companies

  • Parent company (sole shareholder) Neuroplast Beheer B.V. report 1